Adicet Bio (ACET) Payables (2017 - 2026)

Adicet Bio's Payables history runs 10 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Payables fell 33.48% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 33.48% YoY), while the FY2025 annual figure was $4.7 million, down 1.88% from the prior year.
• Payables for Q1 2026 stood at $2.9 million, down from $4.7 million in the prior quarter.
• The five-year high for Payables was $4.8 million in Q4 2024, with the low at $1.9 million in Q2 2024.
• The 5-year median for Payables is $3.5 million (2022), against an average of $3.6 million.
• The sharpest annual moves came in 2022 and 2023: Payables jumped 98.23% in 2022, then sank 40.4% in 2023.
• Adicet Bio's Payables stood at $4.4 million in 2022, then tumbled by 40.4% to $2.6 million in 2023, then soared by 84.0% to $4.8 million in 2024, then slipped by 1.88% to $4.7 million in 2025, then slumped by 38.19% to $2.9 million in 2026.
• Business Quant data shows ACET's Payables at $2.9 million in Q1 2026, $4.7 million in Q4 2025, and $4.3 million in Q3 2025.